PRJNA678418
apatinib-resistance of hepatocarcinoma
Apatinib is a promising drug for the treatment of liver cancer, however the drug resistance mechanism of apatinib in liver cancer is unknown. In order to study the mechanism of apatinib resistance in liver cancer, we constructed human apatinib resistant hepatocarcinoma cell line apatinib-resistance HepG2 . We characterize the epigenomic transcriptomic and proteomic landscape in Apatinib-resistant Cells in liver cancer. It will help us have a deep understand of Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer and a novel perspective about Apatinib-resistant. Finally, we found that the cell cycle related protein RB1 may play an essential role in the apatinib-resistance of hepatocarcinoma. Our research has important biological meaning for the resistance of apatinib and the treatment of liver cancer.